Carolina Reyes Email and Phone Number

Evidence Business Partner-Influence and shape cross-functional strategic plans, including strategic medical plans, pipeline / business development plans, Global evidence generation plans (IEP), and the Integrated Access Plan.-Serve as the primary point of contact on the Evidence Generation team for all products within assigned TA throughout the lifecycle of those products.- During the pipeline and early development phases, work closely with the BD and Pipeline team, Global, and USMA to assess what evidence is needed to facilitate a thoughtful value story upon launch.-Coordinate with cross-functional Access Teams (Access Business Partners,Pricing & Contracting, Customer Segment Strategy, CCM, Access Marketing, other appropriate partners), keeping a tight pulse on what evidence levers could be available to support pricing, contracting, and messaging in alignment with the overall market access strategy.

• Led team developing global market access and health economics strategies in Oncology, Genetic Rare Diseases, Cardiovascular, Reproductive Health and Infectious Disease, resulting in doubling payer coverage of genetic disease testing in the US and 35% increase globally in 2023• Engaged and partnered with payer field teams in US, Europe, Middle East, Asia Pacific, and Greater China to support and execute payer engagements and reimbursement submissions• Decreased operational expenses by 25% through prioritizing strategic planning and budgets for key deliverables, including Payer-partnered research, value messaging, global value dossier, HTA and reimbursement applications.• Ensured alignment of strategic health economics and market access priorities with the Business Units, Product Development, and Medical Affairs from pre-clinical through post-IVD launch

•Achieved $2.5B in revenues by successfully incorporating HEOR / patient-reported outcomes endpoints in clinical trials, regulatory filings, value proposition, and real-world evidence for COVID-19 sotrovimab•Expanded HEOR and Market Access team by 4X, successfully supporting COVID-19 product launch and growing pipeline.•Built relationships with payers, key opinion leaders and policy-makers (ACIP, Kaiser, Veteran's Affairs) to generate payer-relevant real-world evidence supporting product value for influenza, hepatitis and COVID-19 programs•Developed and executed health economics, epidemiology, real-world evidence plans for influenza, HBV, RSV and COVID - 19 portfolio supported by executive decision makers

-Built early pricing and market access strategy capabilities, understanding payer perspective and willingness to pay for infectious disease pipeline-Incorporate payer evidence in clinical development programs (COVID-19, HBV, influenza)-Patient-reported outcomes for regulatory submissions

-Built Health Economics & Outcomes Research and Market Access capability in an infectious disease start-up from early to late stage drug development-Developed real-world evidence of disease burden and unmet need for influenza, RSV among high risk populations

•Initiated Health Economics and Outcomes Research (HEOR) capabilities at Roche diagnostics, specifically focused on next generation sequencing (NGS) technologies• Developed real-world evidence of NGS technologies for oncology and pre-natal testing (AVENIO, Harmony)• Global value dossier, economic models, and publication planning

• Coached, recruited and managed a team of health economists and outcomes researchers Oncology Team to successfully develop and execute evidence generation strategies for 6 productlaunches, resulting in favorable reimbursement and access for Genentech's products.•Ensured efficient budget management and strategic real-world data investments for goal achievement; increased research, tools, FTEs, and publications by 50% in 3 years.• Delivered HEOR strategies for hematology (Rituxan, Gazyva, Venclexta, Rituxan Hycela), breast cancer (Herceptin, Perjeta, Kadcyla, Tecentriq), gynecological cancer (Avastin) and skin cancer franchises (Zelboraf, Erivedge, Cotellic) to support new drug launches and pricing• Consistently managed therapeutic area resources within approved budget

• Managed a team of health economists to lead long-range HEOR strategy for hematology, skin cancer and oncology pipeline (Rituximab, Zelboraf, Erivedge, Gazyva, venetoclax, polatuzumab)• Communicated the clinical and economic value of newly launched oncology products to payers, physicians and policymakers through payer dossiers, advisory boards, publications and promotional materials• Delivered innovative HEOR strategies and tactics to meet the needs of the Medical team, Government Affairs, payer field teams, brand marketing and global market access partners

Led payer evidence planning and health economics strategy to support favorable access for oncology products (Rituxan, Tarceva and pipeline)• Evaluated coverage and reimbursement for companion diagnostics (EGFR, BRAF testing) • Developed societal value assessment of cross-portfolio oncology, resulting in key publications for Pricing & Access • Developed and implemented patient-reported outcomes strategy for obinituzumab(GA101) pivotal trials

• Developed health economic strategy to support business needs throughout the lifecycle of oncology products (Rituxan, Tarceva) for the treatment of non-Hodgkin’s lymphoma, pancreatic cancer, and non-small cell lung cancer • Delivered cost-effectiveness and budget impact models for AMCP dossiers working in collaboration with multi- functional teams and external collaborators• Collaborated with clinical development and regulatory teams to develop patient-reported outcomes strategy for product labeling claims

Led global reimbursement strategy for Electrophysiology and Neurovascular Business Units• Trained marketing and sales teams on CMS/Medicare reimbursement, resulting in the development of high-quality materials for communicating the value of BSC products to field-based teams.• Developed CMS Coverage with Evidence Development protocol for an intracranial stent registry• Assessed reimbursement environment for new products and business development opportunities

• Developed cost-effectiveness models of biological and pharmacologic therapies for rheumatoid arthritis for AMCP dossier and publication • Managed patient-reported outcomes survey of rheumatoid arthritis patients, obtained IRB approval, responsible for study execution and completion • Prepared proposals, budgets, reports and manuscripts